This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Marsh & McLennan (MMC): Will it Disappoint in Q4 Earnings? (Revised)
by Zacks Equity Research
Marsh & McLennan Companies, Inc. (MMC) is scheduled to report fourth-quarter and full-year 2016 results on Feb 2.
Can Cigna (CI) Sustain its Earnings Surprise Streak in Q4? (Revised)
by Zacks Equity Research
We expect Cigna Corp. (CI) to beat earnings expectations when it reports fourth-quarter and full-year 2016 results, on Feb 2.
Marsh & McLennan (MMC): Will it Disappoint in Q4 Earnings?
by Zacks Equity Research
Marsh & McLennan Companies, Inc. (MMC) is scheduled to report fourth-quarter and full-year 2016 results on Feb 2.
Can Cigna (CI) Sustain its Earnings Surprise Streak in Q4?
by Zacks Equity Research
We expect Cigna Corp. (CI) to beat earnings expectations when it reports fourth-quarter and full-year 2016 results, on Feb 2.
Rite Aid Down on Walgreens Deal Offer Price Cut & Delay
by Zacks Equity Research
Rite Aid Corp. (RAD) and Walgreens Boots Alliance Inc. (WBA) jointly agreed upon a Jul 31, 2017 deadline for the deal and slashed the offer price to accommodate more store divestitures that would help gain regulatory approval.
Paylocity Holding (PCTY) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Paylocity Holding Corporation (PCTY) is set to report second-quarter fiscal 2017 results on Feb 2.
Teladoc (TDOC) to Report Q4 Earnings: What's in Store? (revised)
by Zacks Equity Research
Telehealth provider Teladoc Inc. (TDOC) has not confirmed the time/date for its December-quarter earnings release yet, but the report will likely be fairly soon, as they last reported quarterly results on October 27, 2016.
NXP Semiconductors (NXPI) Q4 Earnings: Will it Surprise?
by Zacks Equity Research
NXP Semiconductors NV (NXPI) is set to report fourth-quarter 2016 results on Feb 1.
CVS Health (CVS) Q4 Earnings: A Beat in Store for the Stock?
by Zacks Equity Research
We expect pharmacy innovation company CVS Health Corporation (CVS) to beat expectations when it reports fourth-quarter 2016 results on Feb 9.
Teladoc (TDOC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Telehealth provider, Teladoc Inc. (TDOC ) is scheduled to report fourth-quarter and full-year 2016 results on Jan 27.
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks Bull and Bear of the Day
CVS Debuts Cheap EpiPen Alternative
by Madeleine Johnson
On Thursday, leading drug store chain CVS Health Corp. (CVS) announced that it is now selling a cheaper alternative to Mylan's (MYL) EpiPen.
Rite Aid (RAD) Q3 Earnings Lag, Walgreens Merger on Track
by Zacks Equity Research
Rite Aid (RAD) posted dismal third-quarter fiscal 2016 results.
CVS Health (CVS) Down on Prevailing Risks, Tepid Guidance
by Zacks Equity Research
In Dec 19, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS)
CVS Health Revises View for 2016 & 2017, Declares Dividend
by Zacks Equity Research
CVS Health Corporation (CVS) recently announced strategies to drive long-term growth and shareholders' value.
CVS Health Introduces Transform Diabetes Care Program
by Zacks Equity Research
CVS Health Corporation (CVS) recently unveils Transform Diabetes Care Program which will help the company's PBM clients improve health outcome of diabetic patients.
Target Soars 8% on Strong Q3 Earnings, E-Commerce Growth
by Madeleine Johnson
On Wednesday, shares of everyone's favorite store, Target Corp. (TGT), are soaring, up around 8% to $77 per share in morning trading after the company posted impressive third quarter financial results.
Company News for November 09, 2016
by Zacks Equity Research
Companies in the News are: VRX,CVS,DHI,HTZ
Stock Market News for July 28, 2016
by Zacks Equity Research
Your Next Stock Should Be Making New Highs
by Kevin Matras
This week, Kevin Matras talks about stocks making new highs and why you shouldn't be afraid to buy them. Highlighted stocks include GPK, LNDC, AIZ, CVS and GIII.